Dual GLP-1 + GIP agonist · weight, glucose, sleep apnea and heart · the molecule in Mounjaro and Zepbound
The ReferenceBenefits, protocols and preparationOpen the reference →What this peptide does at the cellular level, in plain words.
Receptor agonist with greater potency than semaglutide in some models.
Dual agonism: also activates GIP receptor. Synergizes metabolic action.
Dual mechanism amplifies appetite suppression vs mono-agonists.
Reports of up to 22.5% body weight loss in phase III studies.

Lose weight & curb appetite
TirzeLeanTirzepatideLowers body weight · Controls appetite and satiety
+ EnergyDriveMOTS-c+ Adds: Preserves and protects muscle
+ CagriFit+CagrilintideReinforces: Lowers body weight
+ TesaFit+TesamorelinReinforces: Reduces visceral belly fat
TirzeLean + CagriFit+Tirzepatide + CagrilintideOn its own or alongside a GLP-1 (retatrutide or tirzepatide): it adds satiety through another pathway (amylin + GLP-1), boosts the effect and helps break a plateau.
TirzeLean + EnergyDriveTirzepatide + MOTS-cAlongside a GLP-1 it preserves the muscle lost while losing weight.
TirzeLean + TesaFit+Tirzepatide + TesamorelinWith a GLP-1 it targets the visceral belly fat the scale cannot tell apart.Tirzepatide is a synthetic dual agonist peptide targeting both GLP-1 and GIP receptors simultaneously, distinguishing it from single-receptor metabolic peptides like semaglutide. As the active molecule in Mounjaro and Zepbound, tirzepatide has been characterized in over 100 clinical and preclinical studies for its effects on glycemic control, body composition, and energy expenditure.
SuperBio Labs Tirzepatide is supplied as lyophilized powder with ≥99% HPLC-verified purity. Each lot ships with a third-party Certificate of Analysis confirming peptide identity by LC-MS, peptide content, and endotoxin levels.
The dual receptor mechanism is what makes tirzepatide a reference compound in metabolic research: GLP-1 activation modulates appetite and glucose-dependent insulin secretion, while GIP activation improves insulin sensitivity and fat metabolism. Beyond weight, its human trials have already shown: sleep apnea (the molecule in Zepbound, December 2024), heart (the molecule in Mounjaro lowers cardiovascular risk in type 2 diabetes since August 2026; SURPASS-CVOT, NEJM 2025: as protective as dulaglutide with 16% fewer deaths from any cause), heart failure with obesity (SUMMIT: 38% fewer hospitalizations or cardiovascular deaths; no indication yet), kidney (21% fewer kidney events than dulaglutide), fatty liver with inflammation (phase 2) and psoriasis with excess weight (phase 3b with ixekizumab, 2026). For type 2 diabetes it is approved from age 10.
Informed professional research use only.
We don't just hand you the vial. Every Tirzepatide purchase includes everything you need to apply it safely, with a clear protocol and our team available 24/7.
Lyophilized · HPLC purity ≥99% · Batch with COA
Sterile diluent · 0.9% benzyl alcohol
21G needle · For peptide reconstitution
10mg → 5 · 20mg → 10 · 1×/week
10mg → 6 · 20mg → 11 · 1 per application + 1 to reconstitute
Free app · Week-by-week protocol, product sheet and usage guide
8 steps · From opening the kit to application
App · Tracking · Human team 24/7
About supplies: the quantity of syringes and wipes adjusts automatically based on the presentation you choose. For extended cycles (BPC-157, GHK-Cu and similar) we cap supplies at 30 days — beyond that, 29G insulin syringes and 70% alcohol wipes are pharmacy items available without prescription in any city.
This product meets all five — your batch COA ships with the kit.
The official protocol included in the kit. If you have pre-existing medical conditions, consult a professional before starting.
Wk 1–4: 1.5 mg → Wk 5–8: 2 mg → Wk 9–12: 2.5 mg → Wk 13–16: 3 mg
Dual GLP-1 + GIP agonist. Same day each week.
The dual incretin with the most human data on the market.
Insulin resistance · superior to semaglutide in SURPASS-2.
Moderate-to-severe apnea with obesity · the molecule in Zepbound, Dec 2024 (SURMOUNT-OSA).
Fatty liver with inflammation: resolved it without worsening fibrosis (phase 2).
A more tolerable entry point than retatrutide.
About −25% in trials.
Diabetes with cardiovascular risk: the molecule in Mounjaro lowers it (Aug 2026); 16% fewer deaths than dulaglutide (SURPASS-CVOT).
With preserved ejection fraction and obesity: 38% fewer hospitalizations or deaths (SUMMIT, phase 3; no indication yet).
With ixekizumab, clear skin plus −10% weight in 27% vs 6% (phase 3b, 2026).
The classic GLP-1 profile, very well documented. In SURMOUNT-1 (5–15 mg): nausea 25–33%, diarrhea 19–23%, constipation 12–17%, vomiting 8–12% (placebo 2–10%). Mostly mild or moderate and concentrated during dose escalation.
Discontinuation due to adverse events was 4–7% (placebo 3%). Others: reflux, fatigue the day after dosing, and muscle loss without enough protein and strength training. Two class notices: if you are having surgery or an endoscopy under sedation, say you use a GLP-1 (slow gastric emptying; FDA label, Nov 2024); and seek care at once for sudden vision loss (NAION, "very rare" with semaglutide per the EMA, Jun 2025; no signal for tirzepatide). If you vomit or have diarrhea, hydrate: dehydration can harm the kidney. Do not use with prior pancreatitis, medullary thyroid cancer or MEN2, pregnancy, or together with another GLP-1.
| CAS number | 2023788-19-2 |
| Molecular weight | 4813.45 Da |
| Purity (HPLC) | ≥99% |
| Format | Lyophilized powder |
| Quantity | 10 / 20 mg per vial |
| Endotoxins | <1.0 EU/mg |
| Storage | −20 °C, protected from light |
| Use | Use under professional judgment |